Elucidation of drug resistance mechanism at metastasis of liver cancer and bile duct cancer

Elucidation of drug resistance mechanism at metastasis of liver cancer and bile duct cancer - Elucidation of drug resistance mechanism at metastasis of liver cancer and bile duct cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000035090

Enrollment

120

Registered

2018-12-03

Start date

2018-12-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cancer, Bile duct cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1: Patient who have primary liver or bileduct cancer and no cancer chemotherapy in the past. 2: Patients who received removal surgery of liver or bileduct cancer in Kanazawa University Hospital. 3: Patients who received sufficient explanation of this study, on a sufficient understanding, written informed consent.

Exclusion criteria

Exclusion criteria: Patients who are judged as being inappropriate for this study by their medical doctor

Design outcomes

Primary

Measure	Time frame
Evaluation of gene expression and correlation between each genes expression in cancer tissues and normal tissues of patients with liver cancer and bile duct cancer.	—

Countries

Japan

Contacts

Public ContactTakuo Ogihara

Graduate School of Pharmaceutical Sciences Takasaki University of Health and Welfare Laboratory of Clinical Pharmacokinetics

togihara@takasaki-u.ac.jp027-352-1180

Outcome results